“Lebrikizumab Improves Atopic Dermatitis and ​Quality of Life in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab: ​ Results From the ADapt Trial”, J of Skin, vol. 9, no. 1, p. s512, Jan. 2025, doi: 10.25251/skin.9.supp.512.